What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.

Company

Jan. 10

Weekly Gain

Intrexon (PGEN 3.76%)

$29.87

27%

TASER International (AXON 0.07%)

$18.68

19%

BlackBerry (BB 1.82%)

$8.76

15%

LightInTheBox (LITB 2.52%)

$9.13

12%

MannKind (MNKD -1.68%)

$5.92

10%

Source: Barron's.

Let's start with Intrexon. The provider of synthetic biology solutions moved higher after announcing that its CEO will present at the J.P. Morgan Healthcare Conference. The presentation will be on Wednesday afternoon, giving the company the opportunity to educate the market on its UltraVector platform that facilitates the design and development of complex biological systems.

TASER moved higher after announcing a flurry of contracts to close out 2013. The stun-gun maker issued a press release detailing more than a dozen weapon deployments and more than two dozen organizations deploying TASER SMART weaponry.

BlackBerry closed higher every single trading day last week. The week kicked off with another executive hire, bringing in someone to run its devices division. BlackBerry then generated some buzz during the CES exposition by talking up smartphones with physical keyboards, like when the company was in its prime.

LightInTheBox moved higher after acquiring a social e-commerce company. LightInTheBox's all-cash deal for Seattle-based Ador gives it a physical stateside presence for the first time. LightInTheBox is based in China, where it sources formalwear and housewares that it sells overseas. Europe currently represents its biggest market. It remains to be seen whether Ador can move the needle for a company that has posted disappointing financials since going public last year, but investors seem to be excited about the push to shake things up by going shopping.

MannKind was on a roller-coaster ride, soaring on Thursday and tumbling on Friday. The Endocrinologic and Metabolic Drugs Advisory Committee is tentatively looking at April for a review of Afrezza, MannKind's potentially game-changing inhalable insulin treatment. If this past week's volatility was wild, one can only imagine the wild swings that wait in April based on the results of the review.